-
February 1, 2012 •
Capital markets/Funding, Drug Development, Science Focus •
832
Governments around the world have made huge investments in academic health research, investments that play a critical role in...
-
December 1, 2011 •
Blogs, Policy/Regulatory/IP •
741
Biosimilars are second entry biologic drugs. They rely in part on data from an already-approved reference product to reduce the...
-
December 1, 2011 •
Blogs, Business Focus, Capital markets/Funding •
729
As the often quoted Chinese curse (with unknown origins) goes – “May you live in interesting times” – it is indeed...